Gemina Laboratories Ltd. (GLABF)
- Previous Close
0.3700 - Open
0.4126 - Bid --
- Ask --
- Day's Range
0.4126 - 0.4126 - 52 Week Range
0.2990 - 0.6957 - Volume
300 - Avg. Volume
1,617 - Market Cap (intraday)
30.438M - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops Legio X, a COVID-19 rapid antigen test that validating the Gemina Surface Chemistry on this platform; and LEGIO X, an influenza AB multiplex lateral flow test. It is also developing a pipeline of products for the diagnosis of infectious respiratory diseases. The company was incorporated in 2017 and is headquartered in Burnaby, Canada.
www.geminalabs.comRecent News: GLABF
Performance Overview: GLABF
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLABF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLABF
Valuation Measures
Market Cap
24.36M
Enterprise Value
24.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
343.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-213.56%
Return on Equity (ttm)
-3,473.52%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.41M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.9k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.21M